First report of safety, PK, and preliminary antitumor activity of the oral EGFR/HER2 exon 20 inhibitor TAK-788 (AP32788) in non-small cell lung cancer (NSCLC). Doebele, R., Riely, G. J., Spira, A. I., Horn, L., Piotrowska, Z., Costa, D., Neal, J. W., Zhang, S., Reichmann, W., Kerstein, D., Li, S., Janne, P. A. AMER SOC CLINICAL ONCOLOGY. 2018

View details for DOI 10.1200/JCO.2018.36.15_suppl.9015

View details for Web of Science ID 000442916003189